Sponsor / Institution

National Institutes of Health Clinical Center

Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.

All Programs Therapeutics Devices

Open filtered programs

Programs

linked to organization

Strong Evidence

0 status confirmed

Details Checked

0 open data checks

Company / Institution Links

0 / 1

industry vs non-industry records

Competitive Density

Pipeline Velocity

Completion Signal

Programs by Stage

Phase 21

Trial / Program Status

Active1

Modality Mix

Small Molecule1

Indication Coverage

Cisplatin-Induced Hearing Loss1

Hearing Loss1

Ototoxicity1

Program Types

Therapeutic1

Population Tags

adult1

cisplatin-ototoxicity1

head-and-neck-cancer1

otoprotection1

Strong-Evidence Records

0 records

No strong-evidence records are linked to this organization yet.

Checked Records With Caveats

1 checked · 0 open checks

NIDCD atorvastatin cisplatin otoprotection study

Details checked

Small MoleculePhase 2Active

Oral atorvastatin 40 mg daily during and after cisplatin-based chemoradiation, evaluated for reduction of cisplatin-induced hearing loss in adults with head and neck squamous cell carcinoma.

Data checks: federal-sponsor, active-recruiting